Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis

Background Clinical trials have shown promising results for interleukin-23 inhibitors in the treatment of psoriasis. The drugs have been used in clinical practice since 2017. Objective To investigate the drug survival and effectiveness of interleukin-23 inhibitors in the treatment of psoriasis and p...

Full description

Bibliographic Details
Main Authors: Cathrine Dawn Büttner Elgaard, Lars Iversen, Kasper Fjellhaugen Hjuler
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Journal of Dermatological Treatment
Subjects:
guselkumab
risankizumab
tildrakizumab
psoriasis
Online Access:http://dx.doi.org/10.1080/09546634.2022.2133531

Similar Items

Similar Items